Aptevo (APVO) Director John Niederhuber Receives 400 Shares

What Happened
John Niederhuber, a director of Aptevo Therapeutics (APVO), had 400 restricted stock units (RSUs) convert into 400 common shares on August 6, 2026. The Form 4 shows an acquisition of 400 shares (conversion) and a simultaneous disposition of 400 shares at $0.00 (derivative). No cash value is reported for these transactions.

Key Details

• Transaction date: August 6, 2026; Form 4 filed August 10, 2026 (timely filed).
• Acquired: 400 shares via conversion of RSUs (price N/A).
• Disposed: 400 shares at $0.00 (listed as derivative).
• Footnotes:
  • F1 — RSUs convert one-for-one into common stock.
  • F2 — Grant: Aug 6, 2025 of 7,200 RSUs (400 post-split) that vest on the first anniversary (i.e., Aug 6, 2026).
• Shares owned after the transaction: not specified in the provided data.
• Filing timeliness: Appears timely (filed within the required two business days).

Context
This was not an open-market buy or sale. The RSUs vested and converted into common stock; the recorded disposal at $0.00 is consistent with the common practice of shares being surrendered or net-settled to satisfy tax withholding or administrative requirements following vesting. The filing reports no cash proceeds and does not indicate a market-direction trade.